This retrospective case series provides Class IV evidence that the C5 complement inhibitors eculizumab or ravulizumab may improve disability in patients with NMOSD when given during or shortly after acute relapse.
Building similarity graph...
Analyzing shared references across papers
Loading...
Rommer et al. (Wed,) studied this question.
www.synapsesocial.com/papers/699010ce2ccff479cfe56f89 — DOI: https://doi.org/10.1212/nxi.0000000000200548
Paulus S. Rommer
Wei Jiang
Julia Nolte
Neurology Neuroimmunology & Neuroinflammation
Johns Hopkins University
Massachusetts General Hospital
Johns Hopkins Medicine
Building similarity graph...
Analyzing shared references across papers
Loading...